ABSTRACT
The project was
conducted to determine the number of sickle cell cases reported in the study
area (Case Study of Hadejia General Hospital Jigawa state) on the documented
data from January,2018-June,2023. The data was analyzed using chi-square
goodness of fit test and trend analysis
and aimed to forecast the level of cases from July to December 2023. So that,
in the analysis of chi-square goodness
of fit test we found that there is significance difference among the gender and
age group, and then in the trend analysis we forecast that the number of cases from July to December 2023.
TABLE OF CONTENTS
Content Pages
Title page …………………………………………………………………………………..i
Declaration …………………………………………………………………………………..ii
Approval page
…………………………………………………………………………………..iii
Dedication …………………………………………………………………………………..iv
Acknowledgement …………………………………………………………………………...v
Abstract …………………………………………………………………………………...vi
Table of Content ……………………………………………………………………...……vii
List of Table ……………………………………………………………………………………ix
List of Figure ……………………………………………………………………………………ix
CHAPTER ONE
1.1
Introduction …………………………………………………………….……………….1
1.2 Historical
back ground …………………………………………………….……………….2
1.3 Statement of
research problem .………………………………………….………………….2
1.4 Aim and
objectives …………………………………………………….……………….3
1.5 Significance
of the study. ……………………………………………………….…………….4
1.6 Scope and
limitation of the study ………………………………………………….………….4
1.7 Research
hypothesis ………………………………………………………….………….4
1.8 Definition
of the term …………………………………………….……………………….4
CHAPTER TWO
2.0
Literature review …………………………………………………….……………….7
2.1
Introduction …………………………………………………………….……………….7
2.2
Causes of sickle cell diseases. …………………………………………….……………….8
2.3
Treatment for sickle cell diseases …………………………………….……………….8
CHAPTER THREE
Research Methodology
3.0 Method of Data Collection ……………………………………………………………10
3.1 Introduction ……………………………………………………………………………10
3.2 Method of data collection ……………………………………………………………………10
3.2.1 Sources of data collection ……………………………………………………………10
3.3 Methodology ……………………………………………………………………………11
3.3.1 Method of data analysis ……………………………………………………………………11
3.3.2 Chi-square test ……………………………………………………………………………11
3.4 Least square method ……………………………………………………………………13
CHAPTER FOUR
4.0
Data presentation and analysis ……………………………………………………………14
4.1
Introduction ……………………………………………………………………………14
4.2
Data presentation ……………………………………………………………………14
4.3
Data analysis ……………………………………………………………………………19
CHAPTER
FIVE
5.0 Summary, Recommendation and Conclusion ……………………………………………25
5.1 Summary ……………………………………………………………………………25
5.2 Recommendation ……………………………………………………………………26
5.3 Conclusion ……………………………………………………………………………26
Reference ………………………………………………………………………………..27-28
LIST
OF TABLE
Table 4.1:
Representation of number of sickle cell cases from January, 2018 – June, 2023 ……14
Table
4.2: Chi-square test (Gender) ……………………………………………….……………19
Table
4.3: Test Statistics (Gender) …………………………………………………………….19
Table
4.4: Chi-square test (Age group) ……………………………………………………20
Table
4.5: Test Statistics (Age group)
………………………………………………………20
Table
4.6: Trend analysis ……………………………………………………………………21
Table
4.7: Model Summary and Parameter Estimates ……………………………………22
LIST OF FIGURE
Figure 4.1: Scatter plot of number of cases ……………………………………………………22
CHAPTER ONE
1.0 INTRODUCTION
1.1 Introduction
Sickle Cells die
sooner than healthy cells. Normally the spleen help filter infection out of the
blood. But sickle cells get stuck in this filter and die. Having fewer healthy
red blood cells causes anemia. The spleen without a healthy spleen, children
are more at risk for serious infections.
There are
several complex types of the sickle cell gene. Some don’t cause symptoms or several
problems, but others do. Talk to your child’s health care provider about the
specific form of sickle cell your child has.
Most children
with SCD will start showing symptoms during the first year of the around 5
months.
Sickle cell
disease is an inherited disorder of the hemoglobin in blood that has a
worldwide impact on health and longevity. Sickle cell disease is characterized
by lifelong hemolytic anemia and a wide variety of painful and debilitating
verso-occlusive event it occurs in
70,000 to 80,000 of African
Mediterranean or middle eastern.
In some
countries the life expectancy for patient with sickle cell diseases is
shortened by about 30 years while in African where comprehensive medical care
is less available death in early childhood is usual in Nigeria the incidence
1-2% of the population.
Medical advance
in management of sickle cell disease has led to significant increase in life
expectancy of this group of patients. Improved public health neonatal screening
parental and patient education advances in red cell transfusion medicine iron
chelating therapy for all likely contributed to this effect of longevity.
Sickle cell
disease understandably concerns millions of Africans in Nigeria there is no
doubt that prevalence of the condition
is increasing especially among urban education elite and in other communities
with access to effective basic health care. There is however a palpable lack of
information and education about disorder within our communities. This will
increase prevalence has encouraged the growth of myths miss information in
appropriate treatment frustration and stigmatization. The frustration has
kindled the desire in many Africans to do something about sickle cell disorder.
1.2 Historical
background of the study
Linus Pauling
and colleagues were the first, 1949, to demonstrate that sickle cell disease
occurs as a result of an abnormality in the red blood cell. This historical
finding was the first time a genetic disease was linked to a mutation of a
specific protein.
Despite the high
burden of sickle cell diseases (SCD) in Nigeria the underlying
haemoglobinopathy profile remain uncertain. Although a number of urbanized area
have hospital-based newborn screening programs, the impact of the diseases in
rural area is unknown.
1.3 Statement of
the problem
Sickle cell
disease is the most common genetic disease that has a debilitating affection on
individual life if not properly managed. Patients with sickle cell disease can
experience a range of conditions and complications. Here are some common ones:
i. Sickle cell
crises: These are episodes of severe pain that can occur in different parts of
the body, such as the bones, joints, chest, or abdomen. The crises can be
triggered by various factors like stress, dehydration, or infection.
ii. Anemia
sickle cell disease: Can lead to chronic anemia, where there is a decrease in
the number of healthy red blood cells. This can cause fatigue, weakness, and
shortness of breath.
iii. Acute Chest
Syndrome: It is a serious complication of sickle cell disease, characterized by
chest pain, fever, cough, and difficulty breathing. It may be caused by
infection, blood clots, or blocked blood vessels in the lungs.
iv. Stroke: The
abnormal sickle-shaped red blood cells can block blood flow to the brain, leading
to a stroke. This can cause neurological damage, paralysis, or even.
1.4 Aim and
objectives
The aim of the
study is to analyse data on cases of sickle cell disease of recorded in Hadejia
general hospital from January 2018 to June 2023. The aim can be achieved
through the following objectives:
1.To determine
whether sickle cell cases depend on gender
2.To determine
whether sickle cell cases depend on age group.
3.To fit linear
model and forecast for July to December 2023.
1.5 Significance
of the study
The research is
significant to the hospital management of Hadejia general hospital to measure
their performance competence and possible ways of improving their service with
regard to sickle cell disease. The research is also important to the entire
community of Hadejia local government to know the preventive measures and the
rate of sickle cell disease in their population. This research with also
benefit the sickle cell organization of Hadejia local government area and
Nigeria at large.
1.6 Scope and limitation
of the study
The scope of
this research will cover the data of sickle cell disease cases recorded at
Hadejia general hospital the data will be used to carry out the statistical
analysis for the purpose of this research. Therefore we only consider the
record patient reported to the Hadejia general hospital.
1.7
Research hypothesis
Ho: sickle cell cases depend on gender and age
group.
H1: sickle cell cases does not depend on gender and age group.
1.8
Definition of the terms
W.H.O
- World Health Organizational
H.B - Hemoglobin
N.S.A.I.D-
Non steroidal Anti-inflammatory Drugs
S.C.A
-
Sickle Cell Anemia
S.C.T -
Sickle Cell Trait
W.H.O: World
Health Organization is specialized agency of the United Nation that is
concerned with international public health. It was established on 7th
April, 1948, and is headquarters in Geneva, Switzerland its predecessor, the
Health Organization, was an agency of the league of nation.
H.B: Hemoglobin:
is a protein molecule in red blood cells that carries oxygen from the lungs to
the body’s tissues and returns carbon dioxide from the tissue back to the
lungs. The normal adult hemoglobin molecule contains two alpha-globulin chains
and two betas –globulin chain.
N.S.A.I.D: Non-
Steroidal Anti-inflammatory Drugs: is a class of analgesic medication that
reduces pain, fever and inflammation. Since most episodes of back pain involved
inflammation, NSAID, such as ibuprofen and naproxen are often an effective
treatment option.
S.C.T: Sickle
Cell Trait is an inherited usually asymptomatic blood condition in which some
red blood cells tend to sickle but usually not enough to produce anemia and
that occurs primarily in individuals of African, Mediterranean, or South West
Asian ancestry who are heterozygous for the gene controlling hemoglobin.
S.C.A: Sickle
Cell Anemia is an inherited form of anemia a condition in which there isn’t
enough health red blood cells to carry adequate oxygen throughout your body.
Login To Comment